SCHEMBL13229489

SCHEMBL13229489

FC(F)(F)c1ccc(-c2ccc3c(c2)N(Cc2c[nH]cn2)CC3)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.43
CDK9 P50750 3/20 0.38
TRPV1 Q8NER1 2/20 0.37
CHKA P35790 1/20 0.36
SCD O00767 1/20 0.36
KIF11 P52732 1/20 0.36
TDP2 O95551 1/20 0.35
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
MAP4K1 Q92918 1/20 0.33
ROCK1 Q13464 1/20 0.33
S1PR1 P21453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528547 0.91 TRPV1 (0.40) HRH3CDK9TRPV1SCDNPC1
SCHEMBL13229487 0.90 HRH3 (0.45) HRH3CDK9TRPV1PRMT5WDR77
SCHEMBL13229483 0.88 HRH3 (0.39) HRH3CDK9TRPV1SCDHDAC1
SCHEMBL13229365 0.88 HRH3 (0.41) HRH3CDK9HDAC1HDAC6
SCHEMBL13229407 0.87 HDAC1 (0.43) HRH3CDK9TRPV1MAPTL3MBTL1
SCHEMBL13229357 0.87 HDAC1 (0.43) HRH3CDK9TRPV1MAPTL3MBTL1
SCHEMBL13229472 0.87 HRH3 (0.45) HRH3CDK9TRPV1MAP4K1S1PR1
SCHEMBL13229397 0.86 CDK9 (0.40) CDK9SCDHDAC1HDAC6
SCHEMBL13229480 0.86 TRPV1 (0.41) CDK9TRPV1HDAC1HDAC6
SCHEMBL13229469 0.85 HRH3 (0.40) HRH3CDK9TRPV1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501747-B2 Functionally selective alpha2C adrenoreceptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US disclosed
US-8501747-B2 Functionally selective alpha2C adrenoreceptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US disclosed
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) 2010-08-05 US disclosed
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) 2010-08-05 US disclosed
WO-2008100456-A2 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS ADRA2C, ADRB2, ADRB3 HRH3 448/4885CDK9 4510/4885TRPV1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.